Janet Sasso

Information Scientist/CAS


Janet M. Sasso earned her B.S. in Biology from The Ohio State University. She also holds her Master of Public Health from OSU where she focused her research on public health equity and education. She joined CAS in 2006 as an Information Scientist in the life sciences department curating pharmacology, pharmaceutical, environmental science, and toxicological research information. She and her team have recently studied the landscape of the gut-brain alliance in respect to mental and gastrointestinal health and disorders.

Emerging Science
Uncover the latest advancements in understanding and treating neurodegenerative diseases like Alzheimer’s, Parkinson’s, and Huntington’s.
July 12, 2024|Insights Report
Emerging Science
Experts from Lawrence Livermore National Lab, Oak Ridge National Lab, The Ohio State University, and CAS discuss major research trends in 2024.
February 15, 2024|Webinar
As cancer is projected to increase, finding stronger therapeutics is more urgent. Biomarkers offer a potential solution for better diagnosis and treatment.
February 9, 2024|Article
Emerging Science
CAS and Excelra delved into data surrounding biomarkers and their relationship to cancer to identify key targets for future study.
February 9, 2024|Insights Report
Drug Discovery
Since 2018, research interest in antibody-drug conjugates has increased exponentially, due to their potential in the fight against cancer.
October 12, 2023|Article
Emerging Science
CAS, Bayer, and Caltech explore how the gut-brain axis influences health from IBS to autism.
September 22, 2023|Webinar
Exosomes have enormous potential in drug delivery, diagnostics, and more. Mayo Clinic, Direct Biologics, and Aruna Bio discuss the full landscape.
March 15, 2023|Webinar
Drug Discovery
Landscape view of emerging contributors, companies, and researchers in the emerging field of exosome research. This article overviews key players in diagnostics and therapeutic fields of exosome research with a deeper look into the current clinical pipeline.
December 15, 2022|Article
Drug Discovery
Expert panelists include Dr. Benjamin Ebert, the chair of Medical Oncology at the Dana-Farber Institute, Dr. Phil Chamberlain, the co-founder, President, and CEO of Neomorph, and Janet Sasso, an information scientist specializing in Life Sciences at CAS.
October 12, 2022|Webinar
Digital R&D
Drug development is rapidly changing, which requires pharma companies to pivot. This is where AI drug development comes in, applying new technology to tackle an old problem.
September 26, 2022|Article
Drug Discovery
As COVID-19 cases rise again worldwide, the Omicron subvariant BA.5 is currently the dominant strain. This blog explores some key mutations that increase transmission, evade protective antibodies, and increase the rate of (re)infection.
July 20, 2022|Article
Molecular glues have been used to uncover new therapeutic agents. Because of their targeted protein degradation that holds them together, these glues have exciting potential in uncovering new drugs to fight cancer, immune diseases, and more.
June 21, 2022|Article
Emerging Science
With recent headlines on monkeypox, learn more about the research landscape, scientific profiles, and currently available therapies. A deeper understanding of the published science enables clarity and insight on this emerging news story.
May 31, 2022|Article
We are in the midst of a therapeutic revolution, according to the authors of a recent review article in Frontiers in Bioengineering and Biotechnology.
May 6, 2022|Article
With recent mRNA booster recommendations, many ask if they should get a COVID-19 booster and what the science shows? This blog explains the science of boosters, reviews current recommendations, and examines recent research.
September 23, 2021|Article